Overview
Overview
NAD+ (nicotinamide adenine dinucleotide) is a critical coenzyme involved in cellular energy metabolism, DNA repair, and mitochondrial function[1]. Clinical research has primarily employed intravenous infusions at high doses, though subcutaneous administration at lower doses is emerging as a practical maintenance route[2][3]. This educational protocol presents a once‑daily subcutaneous approach with gradual titration for improved tolerability. Reconstitute: Add 3.0 mL bacteriostatic water → 333.
- Category
- Longevity
- Routes
- subcutaneous
Mechanism
NAD+
Mechanism of action
Mechanism of action
NAD+ is a coenzyme central to redox reactions, energy metabolism (glycolysis, TCA cycle, oxidative phosphorylation), and cellular maintenance pathways including DNA repair and mitochondrial biogenesis [1] . Cellular NAD+ levels decline with age and metabolic stress, which may contribute to reduced mitochondrial function and impaired cellular resilience [8] . Clinical research on NAD+ therapy has primarily used intravenous infusions at high doses (500–1,000 mg) for applications such as addiction treatment and acute metabolic support [2] [9] . A pilot metabolic study demonstrated that a 750 mg NAD+ IV infusion over 6 hours was well‑tolerated in humans, with rapid metabolic clearance and no acute toxicity [10] . However, IV administration requires clinical supervision and specialized equipment. Subcutaneous (SC) or intramuscular (IM) injections at lower doses (tens to low hundreds of milligrams) are emerging as practical alternatives for maintenance therapy and wellness applications [3] [11] . Compounded NAD+ can be administered SC in small volumes, and SC self‑injection is convenient for ongoing use [12] . Conservative protocols start around 50–100 mg per injection a few times per week; the present protocol uses daily SC administration with gradual titration to optimize individual tolerance and response.
Key research findings
- 01
NAD+ (nicotinamide adenine dinucleotide) is a dinucleotide coenzyme, not a peptide; it is the central electron carrier in redox metabolism (glycolysis, TCA cycle, oxidative phosphorylation) (foundational biochemistry).
- 02
Required co-substrate for sirtuins (NAD+-dependent deacylases), PARPs (DNA-repair enzymes), and CD38, linking cellular energy status to signaling (extensively documented in vitro and in vivo).
- 03
Tissue NAD+ levels are reported to decline with age across multiple species (animal and human observational studies).
- 04
Human studies of NAD+ precursors (nicotinamide riboside, NMN) report increases in blood NAD+ metabolites; downstream functional/clinical endpoints remain under active investigation with mixed results.
- 05
Delivery questions (direct NAD+ versus precursors; oral vs intravenous; cellular uptake) are active areas of research.
Primary source: Oral NR (strongest human RCT base): Multiple RCTs (Martens 2018, Conze 2019, Dollerup 2018, Brakedal 2022) consistently raised blood NAD+ with favorable tolerability at doses up to 1,000 mg/day. Oral NMN (growing human RCT base): Yoshino 2021 showed improved muscle insulin sensitivity at 250 mg/day in postmenopausal women. A 2022 dose-response RCT (Yi et al., Geroscience) at 300/600/900 mg/day raised NAD+ dose-dependently with no safety issues at 60 days. Direct injectable NAD+ (limited human evidence): Historical IV case reports (O'Holleran 1961) plus pilot pharmacokinetic comparisons (e.g. ChromaDex 2024 medRxiv) show IV delivery raises NAD+ rapidly. A 2024 systematic review in the American Journal of Physiology found insufficient high-quality evidence for routine subcutaneous NAD+ practice. Mechanism and biology: Yoshino, Baur, Imai 2018 (Cell Metabolism) and Covarrubias et al. 2021 (Nature Reviews Mol Cell Biol) document age-related NAD+ decline and the biology that drives clinical interest. Ongoing trials: Trials like NCT07328100 (intravenous coenzyme I for vascular aging, 2026 start) and NCT05243290 (oral NR in Gulf War Illness) continue to expand the human evidence base. Evidence gap: Large-scale, long-duration RCTs of subcutaneous NAD+ for wellness or longevity endpoints have not been published as of June 2026.
Protocol Reference
Protocol reference
Commonly cited research range: 50–100 mg, daily.
Reference figures reported in the research literature — not a dosing recommendation. For interactive vial math and scheduling, see the Calculator and Schedule tabs.
Cited protocol & reconstitution guide
Source-backed reference fields by phase, including any volume fields authored in the cited guide.
Assessment
50 mg (weekly total 50 or 150 mg)
Titration
75 mg (weekly total 75–225 mg)
Standard maintenance
100 mg (weekly total 200–300 mg)
| Phase | Reference amount | Units / volume |
|---|---|---|
| Assessment | 50 mg (weekly total 50 or 150 mg) | 50 units (0.50 mL) |
| Titration | 75 mg (weekly total 75–225 mg) | 75 units (0.75 mL) |
| Standard maintenance | 100 mg (weekly total 200–300 mg) | 100 units (1.00 mL) |
Titration protocol
- AssessmentStart50 mg per injection, 1x or 3x weekly (weekly total 50 or 150 mg)
Inject slowly over 5–10 seconds; rotate sites across the four abdominal quadrants, back of the upper arm, and outer thigh.
- TitrationBuild75 mg per injection, 1–3x weekly (weekly total 75–225 mg)
Increase by ~25 mg only if the assessment phase is well tolerated.
- Standard maintenanceBuild100 mg per injection, 2–3x weekly (weekly total 200–300 mg)
Morning timing is commonly preferred. Missed dose: skip and resume at the next scheduled session.
- Loading (Intensive)Maintenance100–200 mg daily for 7–10 days (weekly total 700–1,400 mg during a 7-day week)
Supervised settings only.
Storage & Handling
Storage requirements(typical for most peptides)
Can be stored for extended periods. Protect from moisture.
Store in refrigerator door. Never freeze after reconstitution.
Label vials with reconstitution date. Discard if cloudy.
Reconstitution steps
- 01🌡️Bring the vial to room temperature: let the lyophilized NAD+ vial sit at room temperature for 5–10 minutes before reconstitution.
- 02🧴Clean the stoppers: wipe the NAD+ vial stopper and the bacteriostatic water stopper with separate sterile alcohol swabs.
- 03💉Draw 1 mL bacteriostatic water into a sterile syringe — this 100 mg vial yields 100 mg/mL.
- 04💧Inject down the vial wall: aim the stream down the inside wall, not directly onto the powder, to reduce foaming.
- 05🔄Swirl gently: roll or swirl slowly until fully dissolved; do not shake aggressively.
- 06🏷️Inspect the solution: confirm it is clear and free of particulates; discard if discolored or cloudy.
- 07❄️Important: This guide is for educational purposes only and is not medical advice. For research use only. Not for human consumption.
- 08💉This 100mg vial covers the first 3 steps of the schedule; later steps exceed one vial.
Additional storage notes
Store at −20 °C (−4 °F) or below (ideally −80 °C for multi‑year storage) in a dry, dark environment [6] . Minimize moisture exposure as NAD+ powder is hygroscopic.
Refrigerate at 2–8 °C (35.6–46.4 °F) and use within approximately 14 days [7] . Keep protected from light (UV exposure degrades NAD+).
Do not repeatedly freeze and thaw reconstituted NAD+ solution, as this reduces potency.
Before each use, inspect the solution for clarity. A fresh NAD+ solution should be clear and colorless. Discard if discoloration, cloudiness, or precipitate develops.
Clinical Evidence
Clinical evidence
Research examines age-related NAD+ decline and the effects of NAD+ restoration on metabolism and cellular function, largely in preclinical and early clinical studies.
Oral NR (strongest human RCT base): Multiple RCTs (Martens 2018, Conze 2019, Dollerup 2018, Brakedal 2022) consistently raised blood NAD+ with favorable tolerability at doses up to 1,000 mg/day. Oral NMN (growing human RCT base): Yoshino 2021 showed improved muscle insulin sensitivity at 250 mg/day in postmenopausal women. A 2022 dose-response RCT (Yi et al., Geroscience) at 300/600/900 mg/day raised NAD+ dose-dependently with no safety issues at 60 days. Direct injectable NAD+ (limited human evidence): Historical IV case reports (O'Holleran 1961) plus pilot pharmacokinetic comparisons (e.g. ChromaDex 2024 medRxiv) show IV delivery raises NAD+ rapidly. A 2024 systematic review in the American Journal of Physiology found insufficient high-quality evidence for routine subcutaneous NAD+ practice. Mechanism and biology: Yoshino, Baur, Imai 2018 (Cell Metabolism) and Covarrubias et al. 2021 (Nature Reviews Mol Cell Biol) document age-related NAD+ decline and the biology that drives clinical interest. Ongoing trials: Trials like NCT07328100 (intravenous coenzyme I for vascular aging, 2026 start) and NCT05243290 (oral NR in Gulf War Illness) continue to expand the human evidence base. Evidence gap: Large-scale, long-duration RCTs of subcutaneous NAD+ for wellness or longevity endpoints have not been published as of June 2026.
- 01NAD+ (nicotinamide adenine dinucleotide) is a dinucleotide coenzyme, not a peptide; it is the central electron carrier in redox metabolism (glycolysis, TCA cycle, oxidative phosphorylation) (foundational biochemistry).
- 02Required co-substrate for sirtuins (NAD+-dependent deacylases), PARPs (DNA-repair enzymes), and CD38, linking cellular energy status to signaling (extensively documented in vitro and in vivo).
- 03Tissue NAD+ levels are reported to decline with age across multiple species (animal and human observational studies).
- 04Human studies of NAD+ precursors (nicotinamide riboside, NMN) report increases in blood NAD+ metabolites; downstream functional/clinical endpoints remain under active investigation with mixed results.
- 05Delivery questions (direct NAD+ versus precursors; oral vs intravenous; cellular uptake) are active areas of research.
Evidence maturity varies by compound; much peptide research is preclinical (in vitro or animal-model). Where human data are limited, findings should be read as research observations, not clinical conclusions.
References
Literature references
Published research articles and sources related to NAD+.
- 01Pharmaceuticals (Basel) — Clinical evidence for targeting NAD+ therapeutically: metabolic pathways and therapeutic potential View Source
- 02Current Psychiatry Research and Reviews — NAD+ and enkephalinase infusions attenuate burden in substance use disorder (pilot of 50 cases) View Source
- 03Fagron Academy (US) — NAD+ dosing review: routes, protocols, and case study insights from clinical practice View Source
- 04Jinfiniti (NAD+ Dosage Chart) — NAD+ injection dosage guidance: chart, timing, and safety considerations for titration View Source
- 05Olympia Pharmacy — NAD+ injection (Nicotinamide Adenine Dinucleotide): compounding pharmacy information and dosing guidance View Source
- 06Sigma-Aldrich Product Information — β‑Nicotinamide adenine dinucleotide (NAD+) product specification and stability data View Source
- 07Empower Pharmacy — NAD+ injection (lyophilized): compounding specifications and reconstitution guidance View Source
- 08PMC (Pharmacology & Potential Implications of NAD+) — Comprehensive review of NAD+ metabolism, aging, and therapeutic applications View Source
- 09AgelessRx — NAD+ injection clinical overview and administration protocols View Source
- 10Frontiers in Aging Neuroscience — A pilot study investigating changes in human plasma and urine NAD+ metabolome during 6‑hour IV infusion (750 mg dose) View Source
- 11Pure Bio Labs — NAD+ vial (500 mg): high‑purity peptide product specifications View Source
- 12Fagron Academy (NAD+ Review) — Subcutaneous and intramuscular NAD+ administration: emerging practices for maintenance therapy View Source
- 13Jinfiniti (Dosage Chart) — Human case reports: benefits at 100–300 mg/day ranges for cognitive and metabolic support View Source
- 14American Journal of Physiology (PubMed) — Evaluation of safety and effectiveness of NAD+ in different clinical conditions: a systematic review View Source
- 15Fagron Academy — Dosing considerations: regimens exceeding 200–300 mg/day reserved for supervised therapeutic use View Source
- 16CDC Pink Book (Chapter 6) — Vaccine administration: needle selection and injection technique for subcutaneous route View Source
- 17CDC Subcutaneous Injection Guide — Technique diagram and site guidance for subcutaneous injections (45–90° angle, no aspiration) View Source
- 18NCBI Bookshelf — Best practices for injections: asepsis, site preparation, administration, and rotation to prevent lipohypertrophy View Source
- 19PMC (Subcutaneous Drug Injection Review) — Literature review of factors influencing pain at injection site and volume considerations for subcutaneous route View Source
- 20Pure Lab Peptides — NAD+ 1000 mg product page: quality specifications and batch documentation View Source
Observed Effects
Observed effects in cited research
Commonly reported with SubQ
- Injection-site stinging, burning, redness, or temporary nodules — managed with slow injection and site rotation.
- Nausea, headache, or flushing during early titration — often dose- and rate-dependent.
- Temporary fatigue or paradoxical tiredness in the first few sessions.
- Sleep disruption when injected later in the day.
Commonly reported with IV
- Flushing and warmth, especially with faster infusion rates.
- Chest tightness or shortness of breath at faster infusion rates.
- Mild headache from transient vasodilation.
- Transient increase in heart rate with rapid administration.
Theoretical or longer-horizon concerns
- Long-term human safety data for high-dose injectable NAD+ remains limited.
- Active malignancy is a contraindication because NAD+ supports cellular proliferation.
- Liver and kidney markers are reasonable to track in extended high-dose protocols.
- Most acute observed effects are dose-dependent and rate-dependent. Slower injection, lower starting doses, and morning timing all reduce reported tolerability issues.
Research Considerations
Research considerations
Research Use Only - not for human or veterinary therapeutic use. A well-characterized endogenous/biochemical compound; on this platform it is handled strictly as a research material. Consult a licensed healthcare professional for any clinical decisions.
- Pregnancy and breastfeeding — insufficient safety data.
- Active malignancy — NAD+ supports cellular proliferation, including potentially in cancer cells; oncologist consultation is essential.
- Severe hepatic or renal impairment — high-dose protocols may add metabolic burden.
- Known hypersensitivity to NAD+ formulation components or BAC water preservatives.
- Concurrent high-dose niacin — overlapping NAD+ pathway loads warrant clinician review.
- People on glucose-lowering medications — NAD+ may enhance insulin sensitivity over time; closer glucose monitoring is prudent.
Factors noted in the research literature; not patient-specific medical advice.
Regulatory Status
Regulatory status
RUO
Comparisons
Comparisons
| Compound | Mechanism | Route | Status |
|---|---|---|---|
| NAD+this | An essential coenzyme central to cellular energy metabolism (redox reactions) and mitochondrial function, and a substrate for sirtuins and PARPs in DNA-repair and signaling pathways. | subcutaneous | Investigational / RUO |
| Prostamax | A synthetic tetrapeptide bioregulator (Lys-Glu-Asp-Pro) derived from prostate peptide-complex research, studied for tissue-specific regulatory effects on prostate tissue. | intramuscular | Investigational / RUO |
| SNAP-8 | A synthetic acetylated octapeptide (an extended Argireline analog) studied for topical reduction of muscle contraction by interfering with SNARE-complex formation at the neuromuscular junction. | subcutaneous | Investigational / RUO |
| SS-31 | A mitochondria-targeted tetrapeptide that selectively binds cardiolipin in the inner mitochondrial membrane, stabilizing electron-transport-chain organization and reducing reactive oxygen species. | subcutaneous | Investigational / RUO |
| Testagen | A synthetic tetrapeptide bioregulator (Lys-Glu-Asp-Gly) studied for modulation of endocrine function, particularly pituitary-gonadal regulatory pathways. | subcutaneous | Investigational / RUO |
| Oxytocin | A nonapeptide hormone acting on oxytocin receptors; studied for roles in uterine contraction, lactation, and central modulation of social and affiliative behavior. | subcutaneous | Investigational / RUO |
| PE-22-28 | A synthetic heptapeptide (GVSWGLR) derived from the sortilin propeptide that acts as a selective antagonist of TREK-1 potassium channels, a mechanism studied for mood regulation and neuroplasticity. | subcutaneous | Investigational / RUO |
Attributes shown for research comparison only; not a statement of efficacy or therapeutic equivalence.
FAQ
Frequently asked questions
No. NAD+ is a coenzyme, not a peptide. It is grouped with peptide protocols because it shares the injectable research-use format and overlaps with peptide goals around energy, recovery, and longevity. The phrase "NAD peptide" usually refers to injectable NAD+ rather than a true peptide compound.
A common research-planning SubQ start is 50 mg (about 0.50 mL at 100 mg/mL) once weekly or three times weekly, then escalate by ~25 mg as tolerated. Use the PepPal calculator for exact syringe units.
The most common mix is 7.5 mL of bacteriostatic water for a 750 mg vial, giving 100 mg/mL. A higher-concentration option is 4.5 mL of BAC water for 166.7 mg/mL. The calculator handles custom volumes.
Add 10 mL of bacteriostatic water for a 100 mg/mL solution. Some research-planning protocols use 5 mL of BAC water for a 200 mg/mL high-concentration option, which reduces injection volume but requires more careful syringe measurement.
There is no universal daily dose. Research-planning SubQ models commonly stay at 50-100 mg per injection 2-3x weekly. Loading models use 100-200 mg daily for 7-10 days under supervision. Daily SubQ NAD+ outside loading periods is not standard.
Historical IV protocols used 500-1,000 mg per session. Common research-planning SubQ caps sit around ~300 mg weekly without further evaluation. Doses above 200-300 mg/day are typically reserved for supervised therapeutic use.
Common reports include injection-site stinging, nausea, headache, flushing, and short-term fatigue. Most acute effects are dose- and rate-dependent and improve with slower injection and conservative titration.
Injectable NAD+ is not FDA-approved as a therapeutic. It is available only as a compounded preparation through 503A/503B pharmacies. Oral nicotinamide riboside (NR) holds GRAS/NDI status as a dietary supplement.
Both contain the same NAD+ molecule. Buffered NAD+ ships with a pH stabilizer (most commonly Tris) that brings the reconstituted solution closer to physiological pH (~7-8.5), while unbuffered NAD+ reconstitutes acidic (~pH 3-4) and is more often associated with injection-site stinging. The dosing math is identical for both formats. For a full buyer-side comparison, see the NAD+ buffered vs unbuffered guide .
NAD+ injection delivers the molecule directly. NMN and NR are oral precursors the body converts into NAD+. Oral NR has the strongest human RCT base; NMN evidence is growing. Direct injectable NAD+ has more limited human RCT data but rapid systemic availability.
IV NAD+ commonly produces noticeable acute effects within 24-48 hours. SubQ NAD+ effects are usually more gradual over the first 2-4 weeks of consistent dosing. Larger RCT outcome data for direct injectable NAD+ remains limited.
SubQ NAD+ does not depend on stomach contents because it bypasses digestion. Some researchers prefer morning dosing on an empty stomach for energy-pathway timing, but this is preference-driven rather than evidence-driven.
Peptide Dosing Protocols does not directly sell NAD+. Compare COA-verified suppliers in the PepPal supplier directory and verify current vial size, concentration, and lab testing before any sourcing decision.
No. This page is an educational research reference. NAD+ injection is not FDA-approved. Consult a licensed clinician for personal medical decisions.
Research-use notice
Research Use Only. This educational content and calculation support is intended for private research documentation. It does not provide medical advice, human-use directions, or claims of safety or effectiveness.